ReviewThe Journal of infection2015
Point-of-care testing for respiratory viruses in adults: The current landscape and future potential.
Review in The Journal of infection, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Rapid Molecular Tests for Influenza, Respiratory Syncytial Virus, and Other Respiratory Viruses: A Systematic Review of Diagnostic Accuracy and Clinical Impact Studies.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Pooled it
- Practical Guidance for Clinical Microbiology Laboratories: Viruses Causing Acute Respiratory Tract Infections.Clinical microbiology reviews · 2019Guideline
- Rapid Tests for Influenza, Respiratory Syncytial Virus, and Other Respiratory Viruses: A Systematic Review and Meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017Pooled it
- Clinical impact of a routine, molecular, point-of-care, test-and-treat strategy for influenza in adults admitted to hospital (FluPOC): a multicentre, open-label, randomised controlled trial.The Lancet. Respiratory medicine · 2021Trial
- Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial.The Lancet. Respiratory medicine · 2017Trial
- Association between SARS-CoV-2 testing and antibiotic use in Swiss long-term care facilities: a retrospective multicentric study.JAC-antimicrobial resistance · 2025Article
- Current Evidence and Gaps for Outpatient Respiratory Tract Infection Diagnostics: A Call to Action.Open forum infectious diseases · 2025Article
- Cost-of-illness comparison between clinical judgment and molecular point-of-care testing for influenza-like illness patients in Germany.NPJ primary care respiratory medicine · 2023Article
- Rapid influenza molecular testing in secondary care and influenza surveillance in England: Any impact?Influenza and other respiratory viruses · 2022Article
- Advances in the Rapid Diagnostic of Viral Respiratory Tract Infections.Frontiers in cellular and infection microbiology · 2022Review
- A discussion of syndromic molecular testing for clinical care.The Journal of antimicrobial chemotherapy · 2021Article
- Spotlight influenza: Influenza surveillance before and after the introduction of point-of-care testing in Denmark, season 2014/15 to 2018/19.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2021Article
- Analytical Performances of the Panther Fusion System for the Detection of Respiratory Viruses in the French National Reference Centre of Lyon, France.Microorganisms · 2020Article
- Article
- Molecular point-of-care testing for influenza A/B and respiratory syncytial virus: comparison of workflow parameters for the ID Now and cobas Liat systems.Journal of clinical pathology · 2020Article
- Improved diagnostic policy for respiratory tract infections essential for patient management in the emergency department.Future microbiology · 2020Article
- Current and Future Point-of-Care Tests for Emerging and New Respiratory Viruses and Future Perspectives.Frontiers in cellular and infection microbiology · 2020Review
- Economic and operational impact of an improved pathway using rapid molecular diagnostic testing for patients with influenza-like illness in a German emergency department.Journal of clinical monitoring and computing · 2019Article
- Impact of point-of-care testing for respiratory viruses on antibiotic use in adults with exacerbation of airways disease.The Journal of infection · 2019Article
- Community-Acquired Respiratory Viruses in Transplant Patients: Diversity, Impact, Unmet Clinical Needs.Clinical microbiology reviews · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory viruses are responsible for a large proportion of acute respiratory illness in adults as well as children, and are associated with a huge socio-economic burden worldwide. Development of accurate point-of-care tests (POCT) for respiratory viruses has been listed as a priority by the World Health Organisation and replacing the current paradigm of empirical antimicrobial use with directed use is a listed goal of the movement for reduction in antimicrobial resistance. POCTs for respiratory viruses have previously been limited by the poor sensitivity of antigen detection based tests and by a limited range of detectable viruses. Highly accurate molecular platforms are now able to test for a comprehensive range of viruses, can be operated by non-laboratory staff and can generate a result in approximately 1 h, making them potentially deployable as POCTs. The potential clinical benefits of POC testing for respiratory viruses in adults include a reduction in unnecessary antibiotic use, improved antiviral prescribing for influenza and rationalisation of isolation facilities. We review here the burden of disease, the currently available molecular platforms with potential for POCT use and the existing evidence for clinical and economic benefits of testing for respiratory viruses in adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.